OTC Bulletin Board

S & P Company Insight for NEURO-HITECH INC
 
 Profile

 
Business Summary: Neuro-Hitech, Inc., an early stage pharmaceutical company, focuses on developing drugs for the treatment of degenerative neurological diseases. The company's lead product, Huperzine A, a Phase II clinical trial tested for the treatment of Alzheimer's disease.
 
Address
  1 Penn Plz Ste 1503
  New York , NY 10119-1503
  Phone: 212-594-1215
  Fax: 212-798-8183
Transfer Agent
  Empire Stock Transfer Inc.
Employees:  4
ShareHolders:  123
Founded:  2005
Domicile:  Delaware
 
  
 
 Background

 
Neuro-Hitech, Inc., an early stage pharmaceutical company, focuses on developing drugs for the treatment of degenerative neurological diseases. The company's lead product, Huperzine A, a Phase II clinical trial tested for the treatment of Alzheimer's disease. It has two preclinical development programs, one for anti-amyloid compounds or disease modifying drugs for Alzheimer's disease; and the second for the development of a series of compounds to treat and prevent epilepsy. The company was incorporated in 1996 and is headquartered in New York, New York.
History:  INCORPORATED in Delaware Jan. 12, 2006, as Northern Way Resources, Inc.; and on Jan. 17, 2006, merged a Nevada corporation of the same name (incorporated Feb. 1, 2005) under the name Neurotech Pharmaceuticals, Inc.; name changed to Neuro-Hitech Pharmaceuticals, Inc. Jan. 25, 2006; and to Neuro-Hitech, Inc. Aug. 11, 2006. On Jan. 24, 2006, the company acquired Marco Hi-Tech JV Ltd. for 6,164,006 Common shares through the merger of a wholly owned subsidiary of the company into Marco. Marco Hi-Tech JV Ltd. was incorporated in New York Dec. 11, 1996.
 
Subsidiaries:
Marco Hi-Tech JV Ltd.
 
 
Capital Expenditures, thousand. US Dollars
  Year  Amount
  2007  0
  2006  9
 
Research and Development Expenditures, thousand. US Dollars
  Year  Amount
  2007  3,524
  2006  19,481
 
  
 
 Management

 

Management
OfficersPosition
 Mark  AuerbachChairman
 Reuben  SeltzerVice Chairman
 Matt  ColpoysPresident & Chief Executive Officer
 David  BarrettChief Financial Officer & Chief Accounting Officer
 L. William McIntoshChief Operating Officer
 William  WongChief Scientific Officer
 Alan  KestenbaumExec VP
 Thomas P. WalshInvestor Relations Contact

Directors
 John D. Abernathy
 Mark  Auerbach
 Matt  Colpoys
 David R. Dantzker
 Kevin  Esval
 Reuben  Seltzer
 Phillip  Young
 
  
 
 Annual Report

 
Annual Report
 
Income Statement
  20062005
Sales304,240208,343
Cost of Goods Sold155,014102,637
Gross Profit149,226105,706
Selling general & administrative expenses1,765,486389,706
Research and Development Costs19,480,501678,798
Share-based compensation327,835--
Amortization of deferred compensation130,905--
Total Operating Expenses21,704,7271,068,504
Interest Income147,7307,957
Net income (21,407,771)(954,841)
Share earns. Basic($2.25)($0.11)
Share earns. Diluted ($2.25)($0.11)
Weighted Average Shares9,528,6508,327,056
Operating Income As Calculated(21,553,752)(962,798)
Depr. and Amort.1,749--
 
Balance Sheet
  2006
ASSETS:
Current Assets:
Cash and Cash Equivalents4,705,195
Accounts Receivable25,800
Inventory31,291
Prepaid Expenses23,921
Deferred Charges93,750
Total Current Assets4,879,957
Property and Equipment, net7,246
Total Assets4,887,203
LIABILITIES AND STOCKHOLDERS' EQUITY:
Current Liabilities:
Accounts Payable and Accrued Expenses1,195,744
Total Current Liabilities1,195,744
Stockholders' Equity:
Common Stock $0.001 Par Value11,855
Additional Paid-in Capital28,891,967
Deferred Compensation(1,178,147)
Accumulated Deficit(24,034,216)
Total Stockholders' Equity3,691,459
Total Liabilities and Stockholders' Equity4,887,203
Capital Expenditures8,995
Research & Development Expenditures19,480,501
Equity per Share$0.31
Depr. and Amort. Reserve1,749
Common Shares Cl. A100
Common Shares11,855,135
 
  
 
 Interim Report

 
Interim Report   
 
Data Not Available
 
 
 
 
  
 
 Pro Forma Report

 
Pro Forma Report   
 
Data Not Available
 
 
 
 
  
 
 Quarterly Report

 
Quarterly Report Information   
 
Quarterly Revenue, US$
YearQuarterRevenue
  2008   1190,000
  2007   1190,000
  2007   260,000
  2007   3110,000
  2007   4100,000
  2007   Full Year 460,000
  2006   210,000
  2006   3180,000
  2006   Full Year 300,000
 
 
Quarterly Net Income, US$
YearQuarterRevenue
  2008   1(2,070,000)
  2007   1(1,450,000)
  2007   2(2,370,000)
  2007   3(2,950,000)
  2007   4(2,030,000)
  2006   1(910,000)
  2006   2(850,000)
  2006   3(990,000)
  2006   Full Year (21,407,800)
  2005   Full Year (954,800)
 
 
Quarterly EPS, US$
YearQuarterRevenue
  2008   1(.15)
  2007   1(.12)
  2007   2(.19)
  2007   3(.24)
  2007   4(.16)
  2007   Full Year (.71)
  2006   2(.09)
  2006   3(.11)
  2006   Full Year (2.25)
  2005   Full Year (.09)
 
  
 
 Stock Data

 
 
Capitalization as of 03/31/2008:
 
 Authorized SharesOutstanding Shares
Class A Common $0.001 par100100so1
Common $0.001 par44,999,90014,004,853
Preferred $0.001 par5,000,000None
 
LONG TERM DEBT: None.
 
Common $0.001 par
 
Stockholders:  03/27/2008, 123.
Transfer Agent:  Empire Stock Transfer Inc.   Las Vegas , NV
 
OTC Bulletin Board( Primary): NHPI
 
ExchangeYearHighLow
OTC Bulletin Board20080.00000.0000
Nasdaq Capital Market20078.15003.0100
OTC Bulletin Board200610.73005.0000
 
RECENT DIVIDENDS: Common $0.001 par: None.
 
 
  so1Closely held.